相关实验视频

Updated: Jun 3, 2025

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

组合函数组学确定了HDAC6依赖的辐射抵抗性头癌的分子脆弱性

Sharon Pei Yi Chan¹, Celestia Pei Xuan Yeo², Boon Hao Hong²

¹Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.

Experimental hematology & oncology

|January 12, 2025

概括

这项研究确定了基因组脱乙酶6 (HDAC6) 作为克服抗辐射头癌 (HNCs) 的关键漏洞. 用特定药物向HDAC6可以使瘤重新敏感于放射治疗,为复发性HNC患者提供了新的希望.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
癌症治疗方法癌症治疗方法

背景情况:

放射治疗是头癌 (HNCs) 的首要治疗方法,但局部区域性复发发生在约三分之一的患者中.
瘤和微环境因素有助于放射电阻,限制了救援疗法选择.
使用组合函数组学方法来识别针对耐辐射HNC模型的药物组合.

研究的目的:

理性地设计药物配对,利用耐辐射HNC的分子漏洞.
确定新的治疗策略,以克服HNC的治疗阻力.

主要方法:

利用二次现象优化平台 (QPOP) 对12种药物进行选,以对抗同位素耐辐射HNC模型的组合.
使用组合指数得分和亡反应试验评估药物组合疗效.
通过体内和分子测定,研究了基因素脱乙酶6 (HDAC6) 和其调节轴 (SP1) 在放射电阻中的作用.

主要成果:

确定了泛HDAC抑制剂 (泛胺) 与CHK1/2抑制剂 (AZD7762) 或电离辐射 (IR) 的协同效应,用于重新敏感化抗辐射HNC细胞.
证明HDAC6是一种可针对性依赖,用于逆转辐射电阻,通过与SP1.的交叉声调节来调节.
在患者队列中发现了四个基因特征,可预测放射电阻和潜在的适应HDAC6抑制.

结论:

HDAC6代表了一种有前途的分子脆弱性,用于治疗耐辐射HNC.
针对HDAC6为经历治疗失败的HNC患者提供了潜在的新治疗途径.

关键词:

组合疗法是一种联合疗法.它可以抑制HDAC6的抑制.头癌是头部和部的癌症.无线电阻可以抵抗辐射.

更多相关视频

Isolation and Characterization of a Head and Neck Squamous Cell Carcinoma Subpopulation Having Stem Cell Characteristics

Isolation and Characterization of a Head and Neck Squamous Cell Carcinoma Subpopulation Having Stem Cell Characteristics

Published on: May 11, 2016

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...